FBLG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
FibroBiologics is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some encouraging pipeline progress and insider buying, but the current setup is still weak technically, the company remains loss-making with minimal revenue, and there is no strong proprietary buy signal today. My direct view: hold off and do not buy at this time.
FBLG is still in a bearish longer-term trend, with SMA_200 above SMA_20 above SMA_5, which confirms downside pressure. The RSI_6 at 20.863 is extremely weak and near oversold territory, but it does not yet show a strong reversal signal. MACD histogram is positive at 0.153 but is contracting, suggesting momentum is fading rather than strengthening. Price at 1.34 is below the pivot at 1.516 and only slightly above support at 1.302, so the stock is sitting near support but has not broken into a convincing uptrend. The short-term pattern data suggests only modest upside probability, not a strong entry setup.
["Completed manufacturing of the first two batches of CYWC628 drug product.", "Plans to begin patient dosing for diabetic foot ulcers in Q2 2026.", "Preclinical data from CYPS317 for psoriasis was presented at a major dermatology meeting.", "Insiders are buying, with buying activity increasing 358.82% over the last month.", "H.C. Wainwright kept a Buy rating and raised the price target to $8 from $4."]
["Q1 2026 net loss of about $5 million, driven by increased expenses.", "The company raised only $2.5 million for liquidity, suggesting continued financing dependence.", "Revenue remains effectively zero, showing no meaningful commercial growth yet.", "D. Boral Capital downgraded the stock to Hold after the 1-for-20 reverse split.", "Reverse split news has weighed on investor sentiment and liquidity.", "No recent congress trading data available.", "No major politician or influential figure trading activity was provided."]
Latest reported quarter: Q1 2026. Financial performance remains weak overall. The company reported approximately $5 million in net loss, reflecting higher expenses, and raised $2.5 million to improve liquidity. The prior financial snapshot for 2025/Q4 also showed no revenue, negative net income of $3.244 million, and negative EPS of -1.08. The trend is still pre-revenue and loss-making, with no clear commercial growth yet.
Recent analyst sentiment is mixed. On 2026-04-16, H.C. Wainwright raised its price target to $8 from $4 and kept a Buy rating, citing the reverse split, the recent $3M public offering, and expected diabetic foot ulcer validation progress. However, on 2026-03-26, D. Boral Capital downgraded the stock to Hold from Buy after the 1-for-20 reverse split, highlighting weak near-term sentiment and liquidity concerns. Earlier, on 2026-02-26, H.C. Wainwright lowered its target to $4 from $5 but maintained Buy. Wall Street’s pros view is centered on pipeline progress and potential clinical catalysts; the cons view focuses on dilution risk, reverse-split pressure, liquidity concerns, and continued losses.
